文献速递血栓与止血

静脉血栓栓塞症医疗与血管内治疗的可用性:世界血栓日全球调查

Availability of medical and endovascular therapies for venous thromboembolism: a global survey for World Thrombosis Day.
PubMed 文献 · J Thromb Haemost · 2023-10-12

该调查为世界血栓日十周年开展,评估全球静脉血栓栓塞症(VTE)治疗的可用性、可及性与短缺情况。数据来自69个国家,普通肝素、低分子肝素和维生素K拮抗剂几乎在所有国家可用但存在短缺,直接口服抗凝药在约四分之三国家可用,溶栓药在50%国家短缺,至少一种导管导向治疗系统在77%国家获批、在23%受访机构可用;VTE治疗可及性存在显著地域差异,受经济与地缘政治因素限制。

要点

  • 普通肝素、低分子肝素和维生素K拮抗剂几乎在所有国家可用,但分别有13%、19%和15%的国家报告短缺。
  • 直接口服抗凝药在约四分之三受访国家可用;溶栓药在50%国家报告短缺。
  • 至少一种导管导向治疗系统在77%国家获批,但在仅23%受访机构可用。

核心结论

  • 全球VTE治疗可用性存在显著地域差异,可及性似受经济与地缘政治因素限制。
  • 调查结果凸显VTE治疗短板及全球缺乏统一可用性。

研究设计与样本

  • 为世界血栓日十周年开展的全球调查,收集VTE药物与介入治疗的批准状态、可用性、使用、短缺及分布信息。
  • 数据来自69个国家:欧洲33个、亚洲19个、美洲7个、非洲9个、大洋洲1个。
  • 通过访问或联系国家或洲级药品机构、制造商或分销商及在线药物库收集信息。

主要发现

  • 普通肝素、低分子量肝素和维生素K拮抗剂几乎在所有国家可用,但分别有13%、19%和15%的国家记录到短缺。
  • 直接口服抗凝药在约四分之三的受访国家可用。
  • 至少一种用于肝素诱导的血小板减少症的肠外药物在57%的国家可用,其中9%报告短缺。
  • 溶栓药在50%的国家记录到短缺。
  • 至少一种导管导向治疗系统在77%的国家获批使用,在23%的受访机构可用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on availability, affordability, and accessibility is key for the planning of global strategies to reduce the burden of venous thromboembolism (VTE). OBJECTIVES: A survey was conducted for the 10th anniversary of World Thrombosis Day to assess the availability of VTE therapies worldwide and challenges in uniform implementation. METHODS: We gathered information on the approval status, availability, utilization, occurrence of shortages, and spread of medical and interventional therapies for VTE. Furthermore, we collected information by accessing or contacting national or continental medicines agencies, manufacturers or distributors, and online drug repositories. RESULTS: We obtained data from a total of 69 countries: 33 countries in Europe, 19 in Asia, 7 in the Americas, 9 in Africa, and 1 in Oceania. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists were available in almost all countries, but shortages were recorded in 13%, 19%, and 15% of them, respectively. Direct oral anticoagulants were available in approximately three-quarters of the surveyed countries. At least one parenteral medication for heparin-induced thrombocytopenia was available in 57% of countries and a shortage was reported in 9% of these. Shortage of thrombolytics was recorded in 50% of countries. Overall, at least one type of catheter-directed therapy system was approved for use in 77% of countries and available in 23% of surveyed institutions. Our findings revealed notable geographic disparities in the worldwide availability of VTE therapies, the access to which appeared to be limited by economic and geopolitical factors. CONCLUSION: We anticipate that this comprehensive information will play a pivotal role in highlighting the shortcomings of VTE therapies and the lack of homogeneous availability globally.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Malerba SA, Fumagalli RM, Ay C, et al. Availability of medical and endovascular therapies for venous thromboembolism: a global survey for World Thrombosis Day. J Thromb Haemost. 2023. PMID: 37838241. doi:10.1016/j.jtha.2023.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。